Quantcast

Latest Psoriasis Stories

2014-04-30 12:30:11

Expert Opinion Indicates That Humira and Cimzia Have the Best Clinical Profiles of Key Marketed Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014 /PRNewswire/ --Decision Resources Group finds that, when asked to select the top three most persuasive end points when prescribing a new drug for psoriatic arthritis (PsA), the highest percentages of surveyed United States and European rheumatologists selected the American College of Rheumatology (ACR)...

2014-04-30 08:33:19

Frost & Sullivan: Comparative efficacy data critical for higher uptake since psoriasis is not considered a life-threatening condition MOUNTAIN VIEW, Calif., April 30, 2014 /PRNewswire/ -- The market for moderate-to-severe plaque psoriasis therapeutics is becoming increasingly competitive with the imminent arrival of three promising new drug classes: interleukin-17(IL-17) inhibitors, a janus kinase (JAK) inhibitor, and a phosphodiesterase-4 (PDE-4) inhibitor, the last two being oral therapies....

2014-04-24 12:29:49

First U.S. registry to collect both physician and patient data on psoriatic arthritis PORTLAND, Ore., April 24, 2014 /PRNewswire-USNewswire/ -- To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)--a chronic inflammatory arthritis that affects the joints and tendons--the National Psoriasis Foundation (NPF) and Corrona, LLC (Corrona) are collaborating to give NPF-affiliated researchers access to Corrona's psoriatic arthritis registry, which is the largest...

2014-04-20 23:01:04

ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report in its store. Dallas, TX (PRWEB) April 20, 2014 Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report says that over the last decades, therapeutic options for Plaque...

2014-04-16 08:33:00

CHARLESTON, S.C., April 16, 2014 /PRNewswire/ -- Innocutis, a specialty pharmaceutical company in Dermatologic and Podiatric specialties, is pleased to announce that Nuvail [poly-ureaurethane, 16%] is currently the #1 Prescribed Brand for Nail Dystrophy in both dermatology and podiatry. Nail Dystrophy affects a vast portion of the U.S. population and the medical community has had limited treatment options to effectively address this growing problem. Photo -...

2014-04-14 23:05:22

MarketOptimizer.org offers “Xeljanz (Psoriasis) – Forecast and Market Analysis to 2022” research report in its store. Inquire before buying this report at http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=2000 Dallas, TX (PRWEB) April 14, 2014 Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera et al., 2012). Specifically, adult plaque psoriasis is the focus of this report and is...

2014-04-14 20:22:24

FORT WORTH, Texas, April 14, 2014 /PRNewswire/ -- ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule which works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers. Approved by the FDA on March 21, 2014 and...

2014-04-10 23:24:47

Researchmoz presents this most up-to-date research on "Psoriasis and Hepatitis C Pipeline Review, H1 2014". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market. Albany, New York (PRWEB) April 10, 2014 Researchmoz presents this most up-to-date research on"Psoriasis and Hepatitis C Pipeline Review, H1 2014". The report focuses primarily on quantitative market metrics in...

2014-04-09 08:29:57

DUBLIN, April 9, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/stldww/global_psoriasis) has announced the addition of the "Global Psoriasis Therapeutics Market" [http://www.researchandmarkets.com/research/stldww/global_psoriasis ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the...

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.